Table 1.

Overall and CCL3L1 gene dose–dependent effects of CCR5 haplotypes on risk of developing SLE.

Model, CCR5 haplotype, CCL3L1 gene dose	OR (95% CI)	P
Model 1 (N=1059)
HHE	1.61 (1.25 – 2.07)	<0.001
HHG*2	2.57 (1.71 – 3.86)	<0.001
HHF*1	0.24 (0.05 – 1.10)	0.067
Model 2 (<2 CCL3L1 copies, N=235)
HHG*2	3.03 (1.35 – 6.79)	0.007
HHE	1.83 (1.06 – 3.15)	0.030
HHD	4.24 (0.82 – 21.99)	0.086
Model 3 (2 CCL3L1 copies, N=428)
HHE	1.94 (1.31 – 2.88)	0.001
Model 4 (>2 CCL3L1 copies, N=396)
HHG*2	4.12 (1.79 – 9.41)	0.001
HHF*2	0.64 (0.42 – 0.98)	0.042

^*Model 1, stepwise unconditional logistic regression analysis for association between possession of CCR5 haplotypes and SLE disease susceptibility before accounting for CCL3L1 gene dose; Models 2 to 4, indicate stepwise unconditional logistic regression for association of the CCR5 haplotypes in the context of different CCL3L1 gene dose strata (i.e., <2, 2 and >2 CCL3L1 copies). All stepwise regression models used a probability criterion of P < 0.1. CI, confidence interval; OR, odds ratio. N, number of subjects. The analysis is for the combined three cohorts of SLE.

HH, human haplogroup